Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).

Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.

There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.

This report contains market size and forecasts of Adrenoleukodystrophy Drugs in Germany, including the following market information:

Germany Adrenoleukodystrophy Drugs Market Revenue, 2015-2020, 2021-2026, ($ millions)

Germany Adrenoleukodystrophy Drugs Market Consumption, 2015-2020, 2021-2026, (K Units)

Germany Adrenoleukodystrophy Drugs Production Capacity, 2015-2020, 2021-2026, (K Units)

Top Five Competitors in Germany Adrenoleukodystrophy Drugs Market 2019 (%)

The global Adrenoleukodystrophy Drugs market was valued at 258.8 million in 2019 and is projected to reach US$ 456 million by 2026, at a CAGR of 15.2% during the forecast period. While the Adrenoleukodystrophy Drugs market size in Germany was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adrenoleukodystrophy Drugs manufacturers, suppliers, distributors and industry experts on the impacts of the COVID-19 pandemic on businesses, with top challenges including ingredients and raw material delays, component and packaging shortages, reduced/cancelled orders from clients and consumers, and closures of production lines in some impacted areas.

This report also analyses and evaluates the COVID-19 impact on Adrenoleukodystrophy Drugs production and consumption in Germany


Total Market by Segment:

Germany Adrenoleukodystrophy Drugs Market, By Type, 2015-2020, 2021-2026 ($ millions) & (K Units)

Germany Adrenoleukodystrophy Drugs Market Segment Percentages, By Type, 2019 (%)

Hormone Replacement

Transplant

Others

Germany Adrenoleukodystrophy Drugs Market, By Application, 2015-2020, 2021-2026 ($ millions) & (K Units)

Germany Adrenoleukodystrophy Drugs Market Segment Percentages, By Application, 2019 (%)

Childhood Cerebral ALD

Adrenomyeloneuropathy (AMN)

Addison-only

Others


Competitor Analysis

The report also provides analysis of leading market participants including:

Total Adrenoleukodystrophy Drugs Market Competitors Revenues in Germany, by Players 2015-2020 (Estimated), ($ millions)

Total Adrenoleukodystrophy Drugs Market Competitors Revenues Share in Germany, by Players 2019 (%)

Total Germany Adrenoleukodystrophy Drugs Market Competitors Sales, by Players 2015-2020 (Estimated), (K Units)

Total Germany Adrenoleukodystrophy Drugs Market Competitors Sales Market Share by Players 2019 ($ millions)


Further, the report presents profiles of competitors in the market, including the following:

Bluebird Bio Inc

NeuroVia, Inc.

Orpheris, Inc.

Minoryx